Soleno Therapeutics appoints Matthew Pauls to Board, expanding to seven directors

SOLENO THERAPEUTICS INC

Board increased to seven; Matthew Pauls appointed as Class II director effective August 15, 2023, term expiring 2026.
Pauls brings 30+ years biopharma experience; currently CEO of Savara Inc. (NASDAQ: SVRA) and former CEO of Strongbridge Biopharma.
Granted option for 15,000 shares vesting monthly over 4 years under the Company's 2014 equity plan.
Appointment comes as Soleno advances DCCR for Prader-Willi syndrome toward planned regulatory filing and potential approval.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Matthew Pauls

Director

SLNO · SOLENO THERAPEUTICS INC

Effective: 2023-08-15
Filed: August 16, 2023, 7:59 PM ET

appointed Mr. Matthew Pauls to the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Matthew Pauls was appointed as Director at SOLENO THERAPEUTICS INC.

Action: appointed
Role: Director

Exact text from the filing

appointed Mr. Matthew Pauls to the Board, effective immediately.

View on SEC.gov

SOLENO THERAPEUTICS INC filing history →

Source: SEC EDGAR

accession 0001193125-23-213940

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.